Autocrine interleukin-6 production and highly malignant multiple myeloma: Relation with resistance to drug-induced apoptosis

Blood

Volumn 97, Issue 2, 2001, Pages 483-489

  Frassanito, Maria Antonia ^a   Cusmai, Antonio ^a   Iodice, Giuseppe ^a   Dammacco, Franco ^a,b  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b Section of Internal Medicine and Clinical Oncology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 6 RECEPTOR ALPHA; MONOCLONAL ANTIBODY; PROPIDIUM IODIDE; SYNDECAN; UNCLASSIFIED DRUG;

ANTIGEN BINDING; APOPTOSIS; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; MOLECULAR CLONING; MONONUCLEAR CELL; MULTIPLE MYELOMA; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR GROWTH;

EID: 0035863942     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.2.483     Document Type: Article

References (57)

1. Interleukin-6 in human multiple myeloma
2. Biological and clinical aspects of interleukin-6
3. Interleukin 6 is essential for in vivo development of B lineage neoplasms
4. Predictive value of interleukin-6 and neopterin in patients with multiple myeloma
5. Immunore-active interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma
6. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy
7. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma
8. Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies
9. Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells
10. Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines
11. Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma
12. Interleukin-1 accelerates autocrine growth of myeloma cells through interleukin-6 in human myeloma
13. Cytokine gene expression in human multiple myeloma
14. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
15. Interleukin-6 gene expression in multiple myeloma: A characteristic of immature tumor cells
16. + mature myeloma cells
17. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6
18. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion
19. Role of bone marrow stromal cells in the growth of human multiple myeloma
20. In vitro culture of primary plasmacytomas requires stromal cell feeder layers
21. Long-term bone marrow cultured stromal cells regulate myeloma tumour growth in vitro: Studies with primary tumour cells and LTBMC-dependent cell lines
22. Interleukin-6 inhibits apoptosis of malignant plasma cells
23. Interleukin-6 prevents dexamethasone-induced myeloma cell death
24. Fas/Fas ligand (Fas-L)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells
25. Inhibition of myeloma cell growth by dexamethasone and all trans-retinoic acid: Synergy through modulation of interleukin-6 autocrine loop at multiple sites
26. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells
27. The effect on growth and survival of IL-6 can be dissociated in the U-266-1970/U-266-1984 and HL407E/HL407L human multiple myeloma cell lines
28. Interleukin-6 family of cytokines and gp130
29. Interleukin-6 induces tyrosine phosphorylation of the Ras activating protein Shc, and its complex formation with Grb2 in the human multiple myeloma cell line LP-1
30. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: Involvement of Stat-3 in anti-apoptosis
31. Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein
32. High dose glucocorticoid treatment of resistant myeloma
33. Dexamethasone plus retinoids decrease IL-6/IL-6 receptor and induce apoptosis in myeloma cells
34. Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-γ in multiple myeloma cells
35. Multiple myeloma, macroglobulinemia and monoclonal gammopathies
36. A clinical staging system for multiple myeloma
37. Combination chemotherapy for multiple myeloma
38. Increase in interleukin 6 (IL-6) and IL-6 receptor expression in a human multiple myeloma cell line, U-266, during long-term in vitro culture and the development of a possible autocrine IL-6 loop
39. Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies
40. Detection of altered T helper 1 and T helper 2 cytokine production by peripheral blood mononuclear cells patients with multiple sclerosis utilizing intracellular cytokine detection by flow cytometry and surface marker analysis
41. Th1 polarization of the immune response in Behçet's disease: A putative pathogenetic role of IL-12
42. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry
43. Serum syndecan-1: A new independent prognostic marker in multiple myeloma
44. Endogenous IL-6 and IL-10 contribute to differentiation of CD40-activated human B Lymphocytes
45. Interleukin-6 is expressed by plasma cells from patients with multiple myeloma and monoclonal gammapathy of undetermined significance
46. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1
47. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells
48. Expression of proteoglycan core proteins in human bone marrow stroma
49. Tumor cell heterogeneity in multiple myeloma: Antigenic, morphologic, and functional studies of cells from blood and bone marrow
50. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade
51. shc, Raf-1, and MEK-1 in the IL-5-induced mitogen-activated protein kinase cascade of a growth-responsive B cell line
52. Blockade of mitogen-activated protein kinase cascade signaling in interleukin 6-independent multiple myeloma cells
53. IFN-alfa is a survival factor for human myeloma cells and reduces dexamethasone-induced apoptosis
54. The retinoblastoma protein and cell cycle control
55. Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein
56. Multiple myeloma: Increasing evidence for a multi-step transformation process
57. Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6